Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Easing the PPE Strain During the Pandemic

During the early days of the pandemic, one of the healthcare community’s challenges was a critical lack of PPE to fight the coronavirus. Ryan Madewell, Director of Environmental Services at Hunt Regional Healthcare for Vanguard Resources, spoke about this problem and how Surfacide’s UV-C solutions helped keep front-line workers and patients safe. Even before…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Easing the PPE Strain During the Pandemic

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

During the early days of the pandemic, one of the healthcare community’s challenges was a critical lack of PPE to fight the coronavirus. Ryan Madewell, Director of Environmental Services at Hunt Regional Healthcare for Vanguard Resources, spoke about this problem and how Surfacide’s UV-C solutions helped keep front-line workers and patients safe.

Even before hospitals began to fill up with coronavirus-infected patients, Madewell said the challenge was always how to get more PPE to prepare for those patients.

“We began researching how we were going to be able to get through if we weren’t able to get more PPE or if there was a limited supply, so we landed on UV light. We already had the Surfacide. We’ve been happy with our Helios system for the past seven years. Finding another use for it was great,” he said.

Due to the infectious nature of the virus, Madewell said the situation provided a dual challenge. While never transitioning entirely away from patient safety, it became essential to protect healthcare workers and employees from the virus.

“The fact [was] we had a limited amount of specifically N95s, but disinfectants [also] became hard to come by,” Madewell said. “We had to make some changes and readdress what our processes were going to be, and we made sure everybody stayed safe and had what they needed to do their job.”

When the CDC provided guidance saying UV-C could be used in an emergency to reprocess N95 respirators, and Madewell and his team put a plan together to use Surfacide.

“Not long after we started trial runs, and began reprocessing when it was necessary,” Madewell said. “And we’ve been doing it ever since.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft has introduced a 60% discount for its Dragon Copilot, prompting a reevaluation of how digital health ROI is measured. The initiative targets rural hospitals, while European efforts like EDiHTA highlight the need for a consistent method to price technology evidence. This shift reflects a broader trend in healthcare towards data-driven decision-making and cost assessment.

  • 01Microsoft offers a 60% discount for Dragon Copilot aimed at rural hospitals.
  • 02There's a growing need for a standardized approach to pricing technology evidence in healthcare.
  • 03The European EDiHTA initiative exemplifies the trend of data-driven evaluation in digital health.

Aug 30, 2026

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512